# Beam Therapeutics Reviews BEAM-301 Data for Glycogen Storage Disease

> Beam Therapeutics shares initial Phase I/II results for BEAM-301 in Glycogen Storage Disease Type 1a.
- Title: Beam Therapeutics Reviews BEAM-301 Data for Glycogen Storage…
- Summary: Beam Therapeutics shares initial Phase I/II results for BEAM-301 in Glycogen Storage Disease Type 1a. Beam Therapeutics presented early clinical data showing…
- Keywords: beam therapeutics, beam-301, glycogen storage disease type 1a, phase i ii, clinical data, esgct annual congress, money, business, Beam, Therapeutics, Reviews, Data
- Source: Seekingalpha — https://seekingalpha.com/article/4958115-beam-therapeutics-inc-beam-reviews-initial-phase-i-ii-beamminus-301-data-in-glycogen-storage
- Author: SA Transcripts
- Published: 2026-10-27T17:10:14+00:00
- Read time: 1 min
- Topics: beam therapeutics, beam-301, glycogen storage disease type 1a, phase i ii, clinical data, esgct annual congress, money, business
## Beam Therapeutics Presents BEAM-301 Data
Beam Therapeutics Inc. (BEAM) reviewed initial Phase I/II clinical data for BEAM-301 in Glycogen Storage Disease Type 1a patients.

> Beam Therapeutics Inc. ( BEAM ) Reviews Initial Phase I II BEAM-301 Data in Glycogen Storage Disease Type 1a
## Key Participants on Call
Holly Manning, VP of Investor Relations; John Evans, CEO; Amy Simon, CMO; and Giuseppe Ciaramella, President joined the conference call.
## Data Presented at ESGCT Congress
The company shared findings from the ESGCT Annual Congress where BEAM-301 was tested on Glycogen Storage Disease Type 1a patients.
## Key takeaway

Beam Therapeutics presented early clinical data showing BEAM-301's potential for Glycogen Storage Disease Type 1a patients.